Transgene SA
PAR:TNG
Transgene SA
PAR:TNG
Price:
1.326 EUR
-0.15%
Market Closed
Updated:
May 18, 2024
Transgene SA
Income from Continuing Operations
|
Transgene SA
Income from Continuing Operations Peer Comparison
Comparables:
VLA
NANO
IPH
ALCLS
ABVX
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Transgene SA
PAR:TNG
|
Income from Continuing Operations
-€22.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Valneva SE
PAR:VLA
|
Income from Continuing Operations
-€101.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
Nanobiotix SA
PAR:NANO
|
Income from Continuing Operations
-€39.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-17%
|
|
|
Innate Pharma SA
PAR:IPH
|
Income from Continuing Operations
-€7.6m
|
CAGR 3-Years
-109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Cellectis SA
PAR:ALCLS
|
Income from Continuing Operations
-$116.8m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-13%
|
|
|
Abivax SA
PAR:ABVX
|
Income from Continuing Operations
-€147.7m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
See Also
What is Transgene SA's Income from Continuing Operations?
Income from Continuing Operations
-22.3m
EUR
-22.3m
EUR
Based on the financial report for Dec 31, 2023, Transgene SA's Income from Continuing Operations amounts to -22.3m EUR.
What is Transgene SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
6%
6%
Over the last year, the Income from Continuing Operations growth was 32%. The average annual Income from Continuing Operations growth rates for Transgene SA have been -9% over the past three years , and 6% over the past ten years .
You don't have any saved screeners yet
